Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 468

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 468
---
4, was $705,483 representing a decrease of $2,290,330 compared to $2,995,813 for the year ended December31, 2023. This decrease was mainly due to the reduction in general and administrative expenses and Kadimastem’s efficiency measures during the reporting period which included a reduction in research and development expenses. Net cash used in operating activities for the year ended December31, 2023, was $3,004,813 representing a decrease of $2,950,385 (49.5%), compared to $5,955,198 for the year ended December31, 2022. This decrease was mainly due to the reduction in general and administrative expenses and Kadimastem’s efficiency measures during the reporting period which included a reduction in research and development expenses. Net Cash Used in Investing Activities Net cash received in investing activities for the year ended December31, 2024, was $161,394, reflecting an increase of $70,844 compared to cash used of $90,550 for the year ended December31, 2023. The change was mainly attributed to purchases of fixed assets and changes in pledged cash. Net cash received in investing activities for the year ended December31, 2023, was $90,250, reflecting an increase of $105,120 (53.8%), compared to cash used of $195,370 for the year ended December31, 2022. The change was mainly attributed to changes in bank deposits during the year ended December31, 2023. Net Cash Provided by Financing Activities Over the period 2021 to 2024, Kadimastem raised approximately $17.3million in equity for the issuance of 2,150,844 Kadimastem Ordinary Shares. In the years 2021 to 2024, Kadimastem received grants from the BIRD Foundation, the Israel Innovation Authority and the Australian Innovation Authority totaling $2.65million. 250 Net cash provided by financing activities for the year ended December31, 2024, amounted to $89,270, representing a decrease of $2,311,803 compared to $2,401,073 for the year ended December31, 2023. This increase was primarily due to capital raised by Kadimastem and proceeds from a convertible loan during the year ended December31, 2023. Net cash provided by financing activities for the year ended December31, 2023, amounted to $2,328,073, representing